CJC-1295 (no DAC)

CJC-1295 grew out of research on growth hormone releasing hormone (GHRH), a 44 amino acid signal made in the hypothalamus. The first 29 amino acids of GHRH carry most of its activity, and that fragment is the basis of sermorelin. The "no DAC" version of CJC-1295 is essentially sermorelin with four amino acid substitutions, which is why it is also called modified GRF 1-29 or mod GRF 1-29. Those substitutions were made to slow enzymatic breakdown and raise potency, and they are credited with much of the compound's strength rather than any later add-on. The better known "with DAC" version attaches a drug affinity complex that lets the molecule bind serum albumin in the blood, stretching its half-life to several days. The no DAC form deliberately leaves that off, so it stays short acting and closer to the body's own GHRH signal.

People look into CJC-1295 no DAC to nudge their own growth hormone output rather than inject growth hormone directly. The commonly cited goals are improved sleep quality, faster recovery, and shifts in body composition such as more lean mass and less fat, since growth hormone and its downstream signal IGF-1 are tied to muscle protein synthesis and fat metabolism. By far the most popular pairing is with ipamorelin, a ghrelin receptor agonist that pushes growth hormone release through a separate pathway, so the two are described as working together on the same pulse. Some users choose the no DAC form specifically because it preserves the body's natural burst pattern and does not keep growth hormone elevated around the clock. A lesser discussed appeal is cost, as sermorelin and CJC-1295 no DAC are usually the cheapest options in this peptide family.

CJC-1295 no DAC acts like GHRH, telling the anterior pituitary to release growth hormone, and the pituitary sits outside the blood brain barrier so a circulating peptide can reach it. What sets the no DAC form apart is its short window, with a half-life reported in roughly the 30 to 60 minute range, so it produces a sharp pulse and then lets levels fall back to baseline. That matters because the body releases growth hormone in pulses, and a signal that fades quickly mimics that rhythm instead of flattening it. The DAC version behaves very differently, because binding to albumin extends its half-life to around five days and raises the low point (trough) levels of growth hormone between pulses, which is exactly what the no DAC form avoids. It is also worth noting that the extra potency of this molecule is attributed to the four amino acid changes rather than the DAC, since that boost shows up even in the short acting form.

CJC-1295 no DAC is used as a subcutaneous injection, since peptides of this size are heavily degraded in the digestive tract and poorly absorbed if swallowed. Because it is short acting, discussions of it focus on timing the dose to line up with a natural growth hormone pulse, and many reported protocols favor dosing at night or on an empty stomach. The reasoning given is that food raises somatostatin, the brake on growth hormone, which can blunt the response to an injection. This is a systemic effect rather than a local one, since the peptide travels in circulation to reach the pituitary. None of this should be read as a dosing recommendation, and the practical schedules people describe are extrapolated rather than drawn from controlled trials on this exact peptide.

The honest summary is that CJC-1295 no DAC, or modified GRF 1-29, has essentially no dedicated human studies, a point the clinicians in the source videos repeat plainly. Most of what is claimed about it is inferred from its close relatives, since it is structurally very near sermorelin and shares the GHRH mechanism, and some inferences borrow from the small human literature on the DAC version. That makes confident claims about its exact half-life, dosing, and long term effects difficult to support from clinical data. The broader growth hormone question also carries real caveats, as chronically elevated growth hormone and IGF-1 raise concerns around insulin resistance and, in theory, effects on cell growth. Anyone weighing this compound should treat the mechanistic story as plausible but largely unproven for the no DAC form specifically.

CJC-1295 in any form is not approved by the FDA for human use, and it is sold in the research chemical market rather than as an approved drug. GHRH analogs and other growth hormone secretagogues are prohibited at all times under WADA rules, so this peptide is banned in tested sport. Access through compounding pharmacies has also tightened, as US regulators moved several peptides in this category off the readily compoundable list, which is why availability keeps shifting. It travels under several names, including modified GRF 1-29, mod GRF 1-29, and tetrasubstituted GRF (1-29), and is frequently confused with the longer acting DAC version and with sermorelin. Rules in this space change quickly, so current status should be verified rather than assumed.